US EditionArcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - Arcutis Biotherapeutics
Summary by Arcutis Biotherapeutics
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - Arcutis Biotherapeutics
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments including topical steroids Second poster will highlight improvements in patient-related outcomes with ZORYVE® (roflumilast) foam 0.3% in psoriasis of the scalp and body WESTLAKE VILLAGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) — Arcutis B…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
